ABOUT THIS DESK
What AMW Peptides Is
A quiet briefing on the published research — not a store, not a clinic, not a consultancy.
What this briefing is
AMW Peptides is a quiet briefing on the research. It covers three research peptides — sermorelin, CJC-1295, and tesamorelin — that sit in the class researchers call growth hormone-releasing hormone analogs. These compounds have drawn heavy scientific and public interest because they act upstream on the pituitary's own GH machinery rather than supplying growth hormone directly. That premise is genuinely interesting. The evidence behind it is uneven, and part of the job here is to say so plainly.
This is not a store. It sells nothing. It holds no commercial relationship with any peptide manufacturer, compounding pharmacy, clinic, or supplement brand, and it takes no sponsored content or affiliate arrangements.
This is not a clinic or a medical practice. It offers no consultations, prescriptions, or individualized health guidance. There is no practitioner here, and nothing on the site should be read as medical advice.
What the briefing does: it reads the published literature, summarizes it with citations, names the gaps, and keeps controlled-trial findings apart from community-reported anecdote. The goal is a quiet, accurate map of what the science shows, for anyone who wants to follow it.
Editorial method
Literature for the briefing is chosen by following the citations that carry weight: primary clinical trials, peer-reviewed pharmacology reviews, regulatory-agency briefings, and government health databases (PubMed, ClinicalTrials.gov, NIH LiverTox). Each piece of evidence is cited by reference number; the full bibliography sits on the references page.
Claims are pinned to their source and species. A finding in rats is reported as a finding in rats. A finding in a 52-week RCT in HIV-positive adults on antiretroviral therapy is reported with those qualifiers intact — not generalized to all adults or all GH-axis questions. Where a finding comes from an editorial opinion rather than a clinical trial, the page says so. Where community-reported effects come from user forums and wellness-clinic write-ups rather than controlled data, they are labeled explicitly as anecdotal.
When the evidence cannot support a claim, the briefing states that the evidence is insufficient. That is not a hedge — it is the finding. One of the main things a literature briefing can do is stop the gap between mechanism and clinical proof from being quietly closed in prose.
Content is checked for accuracy against the primary sources cited. No AI-generated citations are used; every reference in the bibliography is a real published source. If you spot an error or a broken link, flag it through the contact page.
Standing and disclaimer
AMW Peptides is self-operated and answers editorially to the evidence, not to any outside interest. Nothing here is written to promote, market, or sell any compound, product, or service.
Research peptides — the three covered in this briefing included — are not approved medicines for general use (with the specific exception of tesamorelin's narrow HIV-lipodystrophy indication). They are sold by research suppliers for laboratory research use. Content on this site describes what published research has found; it is not a recommendation to use, acquire, or administer any compound.
Growth hormone-releasing hormone analogs are prohibited in competitive sport under the World Anti-Doping Agency Prohibited List. Athletes subject to anti-doping rules should be aware of this.
For any health decision, consult a qualified medical professional.